Pharmaceutical - AstraZeneca, Antibiotics and Infectious diseases

Filter

Popular Filters

AstraZeneca to spin-out early-stage antibiotic R&D into stand-alone company

AstraZeneca to spin-out early-stage antibiotic R&D into stand-alone company

28-02-2015

Anglo-Swedish pharma major AstraZeneca is changing the structure of its small-molecule early-stage anti-infectives…

Antibiotics and Infectious diseasesAstraZenecaMergers & AcquisitionsPharmaceuticalResearchUK

FDA advisory panel backs Actavis’ ceftazidime-avibactam

06-12-2014

Ireland-headquartered generic drugs major Actavis says that the Anti-Infective Drugs Advisory Committee…

ActavisAntibiotics and Infectious diseasesAstraZenecaceftazidime-avibactamPharmaceuticalRegulationUSA

Six hospital-acquired pneumonia drugs in late-stage development could generate $3.8bn by 2020

Six hospital-acquired pneumonia drugs in late-stage development could generate $3.8bn by 2020

09-09-2014

Six drugs currently in Phase III studies to treat hospital-acquired pneumonia would generate a total…

AmikacinAntibiotics and Infectious diseasesAstraZenecaBayerceftazidime-avibactamceftolozaneCubist PharmaceuticalsGSKHospital-acquired pneumoniaPharmaceuticalResearchUSA

AstraZeneca reports positive results from Phase III antibiotic study

AstraZeneca reports positive results from Phase III antibiotic study

19-08-2014

Anglo-Swedish drug major AstraZeneca has achieved positive results from the pivotal Phase III studies…

ActavisAntibiotics and Infectious diseasesAstraZenecaavibactamCeftazidimeComplicated intra-abdominal infectionsForest LaboratoriesMedicinePharmaceuticalResearchSerious bacterial infectionsUK

AstraZeneca signs deals for antibiotic and cardiovascular research

AstraZeneca signs deals for antibiotic and cardiovascular research

28-01-2014

Anglo-Swedish drug major AstraZeneca has entered into further collaborations to expand its research base,…

Antibiotics and Infectious diseasesAstraZenecaCardio-vascularFOB SynthesisLicensingPharmaceuticalResearch

EMA advisory unit issues bunch of positive recommendations

EMA advisory unit issues bunch of positive recommendations

22-11-2013

At its late November meetings, the European Medicines Agency’s Committee for Medicinal Products for…

AB ScienceAnti-viralsAntibiotics and Infectious diseasesAstraZenecaBristol-Myers SquibbDeltybaDiabetesEuropeGilead SciencesLucaneLucane PharmaMasicanOncologyOtsukaPharmaceuticalRegulationSovaldiTivicayViiV HealthcareXigduo

A*STAR and AstraZeneca link to combat Gram-negative bacterial infections

A*STAR and AstraZeneca link to combat Gram-negative bacterial infections

05-11-2013

Two units under Singapore’s Agency for Science, Technology and Research (A*STAR) have signed a joint…

A*STARAntibiotics and Infectious diseasesAstraZenecaPharmaceuticalResearch

Antibiotic ceftaroline fosamil shows promise for treating MRSA pneumonia

12-09-2013

A drug approved just two years ago for treating bacterial infections may hold promise for treating the…

Antibiotics and Infectious diseasesAstraZenecaceftaroline fosamilForest LaboratoriesPharmaceuticalResearchTeflaroZinforo

AstraZeneca's Brilinta gains Class I in ACCF/AHA Guidelines; enters deal with Progenics

18-12-2012

Anglo-Swedish drug major AstraZeneca (LSE: AZN) announced yesterday that a combined panel of experts…

Antibiotics and Infectious diseasesAstraZenecaBrilintaCardio-vascularLicensingMedImmunePharmaceuticalProgenics PharmaceuticalsRegulation

AstraZeneca inks deal for Optimer's fidaxomicin in Latin America

04-12-2012

USA-based Optimer Pharmaceuticals (Nasdaq: OPTR) says it has executed an exclusive agreement with Anglo-Swedish…

Antibiotics and Infectious diseasesAstraZenecafidaxomicinLicensingOptimer PharmaceuticalsPharmaceuticalSouth America

AstraZeneca gains rights to Ardelyx program; GSK returns cUTI candidate GSK2251052 to Anacor

08-10-2012

Anglo-Swedish drug major AstraZeneca (LSE: AZN) this morning announced a worldwide exclusive licensing…

Anacor PharmaceuticalAntibiotics and Infectious diseasesArdelyxAstraZenecaGastro-intestinalsGenito-urinaryGlaxoSmithKlineGSK2251052LicensingNephrology and HepatologyPharmaceuticalRDX5791Research

Pharmaceutical majors unite in Japan to combat H. pylori

18-09-2012

On August 31, nine pharmaceutical companies operating in Japan (Kyowa Hakko Kirin, Takeda Pharmaceutical,…

Antibiotics and Infectious diseasesAsia-PacificAstraZenecaGastro-intestinalsPharmaceuticalRegulationTakeda Pharmaceuticals

AstraZeneca poaches Roche exec as CEO; Gets EU approval for Zinforo

28-08-2012

Anglo-Swedish drug major AstraZeneca (LSE: AZN) this morning revealed that Pascal Soriot from rival Switzerland-based…

Antibiotics and Infectious diseasesAstraZenecaEuropeManagementPharmaceuticalRegulationRocheZinforo

AstraZeneca/BTG abandon CytoFab for sepsis as it fails in Ph IIb

09-08-2012

Anglo-Swedish drug major AstraZeneca (LSE: AZN) has decided to halt any further development of AZD9773…

Antibiotics and Infectious diseasesAstraZenecaBTGCytoFabLicensingPharmaceuticalResearch

News briefs: TB drug developments at Jansen and AstraZeneca; NPS/Amgen deal amended

03-07-2012

US health care giant Johnson & Johnson's (NYSE: JNJ) Janssen Research & Development unit has submitted…

AmgenAntibiotics and Infectious diseasesAstraZenecabedaquilineBiotechnologyCellworkscinacalcetJanssenJohnson & JohnsonLicensingMetabolicsNPS PharmaceuticalsPharmaceuticalRegulationResearch

Back to top